Last edition
News about
GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers
GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.
Indian Pharma's Turning Point: Can the Generics Giant Become a Global Innovator?
India’s pharma industry, long known as the “pharmacy of the world,” now aims to become an innovation hub. To understand this transition, Pharma Industrial India spoke to experts on moving beyond generics toward becoming an “innovator of the world.”
Oncodesign Services Expands Collaboration with GIP ARRONAX to Advance Targeted Radiotherapy Research
Oncodesign Services strengthens partnership with GIP ARRONAX to secure access to rare radionuclides like astatine-211, supporting preclinical development of next-generation targeted radiotherapy treatments for cancer and other diseases.
Hoth Therapeutics Reports Positive HT-VA CRADA Data
Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.
India Pharma 2026: Policy Push and Innovation Fuel Pharmaceutical Industry Growth
9th India Pharma highlights policy support and innovation as key drivers of growth, with leaders emphasising biosimilars, specialty medicines and stronger industry-academia collaboration.
ImageneBio Raises USD 30 Million in Private Placement
ImageneBio has raised USD 30 million in private placement led by Coastlands Capital to advance IMG-007 development in alopecia areata and atopic dermatitis.
Allogene Reports ALPHA3 Data: Cema-Cel Shows 58 Percent MRD Clearance in LBCL
Allogene reports ALPHA3 interim data showing 58 percent MRD clearance with cema-cel in LBCL, rapid ctDNA reduction and favourable safety profile with no serious adverse events.
ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules
ANI Pharmaceuticals launches Carbamazepine extended-release capsules, a generic version of Carbatrol.
Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer
Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.
MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial
MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy